Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Hodgkin Disease 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Endocrine Gland Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 113130-nm albumin-bound paclitaxel 64Albumin-Bound Paclitaxel 43Fluorouracil 37pembrolizumab 35Magnetic Resonance Spectroscopy 35Irinotecan 34Taxes 33Specimen Handling 33Leucovorin 33Oxaliplatin 31Biopsy 22Cyclophosphamide 21Nivolumab 18Cisplatin 17fludarabine 16Radiosurgery 16Drug Therapy 15Capecitabine 12folfirinox 11durvalumab 11Radiotherapy 11Carboplatin 11Blood Specimen Collection 11irinotecan sucrosofate 10Ipilimumab 10Cetuximab 10olaparib 9Standard of Care 9dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Biopsy, Large-Core Needle × 1 year × Clear all
NCT05053971 2026-04-13

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Recruiting
49 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡